Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice

Journal of Psychopharmacology
Yusuke NakataMasaomi Iyo

Abstract

Dopamine supersensitivity psychosis (DSP) is observed in patients with schizophrenia under antipsychotic treatment, and it is characterized by rebound psychosis, an uncontrollable psychotic episode following a stable state and tardive dyskinesia. DSP, first described in patients taking typical antipsychotics in the late 1970s, sometimes appears even in patients who are treated with current atypical antipsychotics. It was recently demonstrated that DSP can have a negative impact on the long-term prognosis of schizophrenia patients and that DSP could be involved in the etiology of some cases of treatment-resistant schizophrenia. Accumulating evidence suggests that an up-regulation of dopamine D2 receptors (DRD2) in the brain caused by long-term exposure to antipsychotics is related to the DSP phenomenon. The present review describes the clinical characteristics and the etiology of DSP in the era of second-generation antipsychotics for patients with schizophrenia. Based on the mechanism of DSP, several potential treatments for patients presenting with a DSP episode or the dopamine supersensitivity state are also discussed.

References

Nov 1, 1978·The American Journal of Psychiatry·G ChouinardL Annable
Jun 24, 1976·Nature·Philip SeemanK Wong
Nov 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·Philip SeemanK Wong
Jul 1, 1987·The American Journal of Psychiatry·R S KeefeK L Davis
Jan 1, 1980·The American Journal of Psychiatry·G Chouinard, B D Jones
Nov 1, 1994·Progress in Neuro-psychopharmacology & Biological Psychiatry·Guy ChouinardR Miller
Aug 1, 1995·Psychiatric Services : a Journal of the American Psychiatric Association·M G Juarez-ReyesW A Hargreaves
May 24, 2003·Behavioural Processes·Silvânia M.M. VasconcelosGlauce S.B. Viana
Nov 13, 2004·European Archives of Psychiatry and Clinical Neuroscience·K H KhoD H Linszen
Mar 2, 2005·Journal of Clinical Psychopharmacology·Mario Rodrigues Louzã, Debora Pastore Bassitt
Jul 29, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Philip Gorwood
Mar 16, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anne-Noël SamahaShitij Kapur
Jun 3, 2008·Schizophrenia Research·Rajiv TandonHenry A Nasrallah
Oct 14, 2008·Psychiatry Research·Pierre-Michel Llorca
Dec 1, 2006·Neuropsychiatric Disease and Treatment·Leslie Citrome
Feb 10, 2011·Pharmacological Reviews·Jean-Martin Beaulieu, Raul R Gainetdinov
Mar 24, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Michael J PelusoPeter B Jones
Jun 14, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomoko InoueNoboru Yamaguchi
Jul 19, 2012·Expert Opinion on Pharmacotherapy·Eric Fakra, Jean-Michel Azorin
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWorld Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Feb 1, 2012·Therapeutic Advances in Psychopharmacology·Paul FallonBill Deakin
Mar 12, 2015·Human Psychopharmacology·Bonginkosi ChilizaRobin Emsley
Oct 29, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alexandra CharronAnne-Noël Samaha
Nov 7, 2015·The American Journal of Psychiatry·T Scott StroupMark Olfson
Jan 10, 2017·International Clinical Psychopharmacology·Yusuke NakataMasaomi Iyo
Jun 26, 2017·Psychotherapy and Psychosomatics·Guy ChouinardMasaomi Iyo

Citations

May 2, 2019·Journal of Psychosocial Nursing and Mental Health Services·Barbara J Limandri
Jun 2, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Christoph U CorrellJ Kane
May 2, 2019·Frontiers in Pharmacology·Antonio VitaMassimo Gennarelli
Aug 23, 2020·Brain Sciences·Ansley Grimes Stanfill, Xueyuan Cao

Related Concepts

Intropin
Psychoses, Drug
Schizophrenia
Antipsychotic Effect
Dopamine D2 Receptor
Central Nervous System Sensitization
Dopamine D2 Receptor Antagonists
Brain
Dopamine
Psychotic Disorders

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here